Close menu




November 13th, 2020 | 13:13 CET

Varta, Royal Helium, Deutsche Telekom - Buy the future!

  • Investments
Photo credits: pixabay.com

When it comes to the DAX, the first thing to do is to take a breather. After the brilliant Biden-BioNTech rally, the leading German index started to move south. And today, not only did companies listed on the DAX release encouraging quarterly figures but companies like Merck and Siemens, Deutsche Telekom, in particular, raised its forecast. Also, in the segments below, there were spectacular figures. After the setback in the markets, there are some buying opportunities here.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: CA78029U2056 , DE000A0TGJ55 , DE0005557508

Table of contents:


    Magenta shines

    Following the report on the Q3 figures, the Bonn Company shone with a forecast increase. The marriage of the US subsidiary T-Mobile US to its smaller competitor Sprint proved to be an absolute stroke of luck.

    "We are raising our forecast thanks to good business on both sides of the Atlantic," said Deutsche Telekom CEO Tim Höttges on Thursday when presenting the quarterly figures. Europe's largest telecoms group now expects adjusted operating profit, excluding lease expenses, of at least EUR 35 billion in 2020 instead of the previous figure of around EUR 34 billion. "I don't know if I will ever see this again," said Höttges, referring to the EUR 1 billion increase.

    Rising demand

    Besides hydrogen, helium is the most abundant element in the universe. Hydrogen is booming at the moment. The applications for helium are also extensive and, at least, as essential. There has been a substantial increase in demand in recent years in the health care sector and in manufacturing. Also, the topic of space travel is becoming increasingly important. NASA is already the largest single customer for helium dealers. When launching rockets, helium is required for the pressure regulation of the fuel tanks.

    Few suppliers

    There are only a handful of pure helium companies on the stock market, which allow investors to participate in the future development of the commodity. The Canadian Company Royal Helium focuses on the procurement of this noble gas. The gas cannot be produced artificially, and it is usually extracted from underground deposits. Royal Helium has access to around 400,000 hectares of licenses for the noble gas in North America, making it one of the largest market players. The Company recently announced that it has received helium permits for an additional 32,166 hectares in the southeast half of Royal's property in Saskatchewan, Canada, where the total area of helium leases and approved concessions now totals approximately 4,320 square kilometers.

    Strong forecasts

    The Canadian analyst firm Cormark Securities Inc. highlights the advantages and enormous opportunities of Royal Helium. The expert Michael Mueller, therefore, gives a buy rating with a target price of USD 0.80 as an initial assessment. The current price is USD 0.29, a difference of more than 100%.

    Great numbers, as expected

    Varta was able to increase its sales of the first nine months to EUR 630.3 million. This means a plus of almost 160% compared to the same period of the previous year. Without the acquisition of Consumer Batteries, it would still be an increase of nearly 70%. The Ellwangen-based Company was also able to shine with a definite plus of 180% in the operating result for the first nine months, which now amounts to EUR 176.8 million.

    Forecast increase logical

    Herbert Schein, the CEO of Varta, continues to assume that the boom in wireless headphones will continue. "The trend among cell phone manufacturers is clear: cable is a thing of the past," Schein said on Thursday. "Soon, the only interface to the devices will be wireless." Accordingly, the annual forecast has been raised from EUR 840 million to EUR 860 million. Previously, the Company had only assumed sales of up to a maximum of EUR 830 million. Earnings before interest, taxes, depreciation and amortization adjusted for special effects should reach EUR 230 million to EUR 235 million, after EUR 97.5 million in the previous year. Here, management assumed only EUR 215 million.

    Faster, faster and faster

    Already in 2021, the magic threshold of EUR 1.0 billion turnover should fall. There is a primary goal for the M-DAX-listed Company in the near future. The production speed is to be increased by 50% next year, making it even more efficient. Varta plans to increase production capacity to 300 million batteries per year by the end of 2021.

    Share price goes down

    Although the figures were very well received, the forecasts were criticized as too conservative. Various analyst firms were of different opinions. After the figures, the experts at Warburg renewed their sell recommendation for the Varta share. The experts see the price target at EUR 80.00. The reason for the sell recommendation is the increased competition, as Samsung, for example, also wants to become active in the battery sector. In contrast, Berenberg is sticking to its buy recommendation with the target price raised from EUR 140.00 to EUR 145.00. In any case, according to the figures, the share price fell to EUR 116.00, a drop of almost 5%.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read